Department of Obstetrics and Gynecology, Ascension Saint Francis Hospital, 355 Ridge Ave, Evanston, IL, 60202, USA.
Department of Obstetrics and Gynecology Edward-Elmhurst Medical Group, 100 Spalding Dr #406, Naperville, IL, 60540, USA.
BMC Womens Health. 2023 Oct 17;23(1):541. doi: 10.1186/s12905-023-02707-3.
To evaluate the quality of life in patients treated for submucosal leiomyomas after hysteroscopic myomectomy compared to medical therapy. This is the first prospective randomized analysis comparing outcomes of medical therapy versus hysteroscopic myomectomy using the TruClear™ hysteroscopic tissue removal system to treat heavy menstrual bleeding from submucosal leiomyoma(s).
Setting: private practice and community-based hospital; subjects: female patients with symptomatic submucosal leiomyomas from 2014 to 2017. A total of 69 patients enrolled, with 47 completed.
randomization, linear mixed-effects modeling, hypothesis testing, and intent-to-treat analysis. Each patient was randomized to oral contraceptive pills/progesterone releasing intrauterine device or hysteroscopic myomectomy. Each patient was to complete the Uterine Fibroid Symptom and Health-related Quality of Life (UFS-QOL) questionnaire at baseline, one month, three months, and greater than or equal to six months after treatment.
Primary outcome was the health-related quality of life (HR-QOL), as reflected from UFS-QOL scores. Contrasts were constructed from a linear mixed-effects model to compare the two treatment groups for changes from baseline in UFS-QOL scores.
UFS-QOL scores were similar at baseline between the two treatment groups. There was an overall improvement in all UFS-QOL scores within each group. Higher improvement scores were noted in the surgical group compared to the medical group for almost all UFS-QOL scores. At ≥ 6 months, in comparison to the medically managed patients, the most considerable score improvements for the surgical group were reported in HR-QOL concern, activities, self-consciousness and symptom severity scores having mean change scores (95% CIs) of 35.3, 28.9, 28.6, and 32.2, respectively.
Although there was no statistical difference in the change degree of improvement of overall quality of life among patients with symptomatic submucosal leiomyomas who received medical or surgical treatments in the study, there were greater differences in improvements in health-related quality of life scores over time after surgical treatment.
评估接受宫腔镜子宫肌瘤切除术治疗的黏膜下肌瘤患者的生活质量与药物治疗相比。这是首次前瞻性随机分析,比较了使用 TruClear™宫腔镜组织切除系统治疗黏膜下肌瘤(s)引起的月经过多的药物治疗与宫腔镜子宫肌瘤切除术的结果。
设置:私人执业和社区医院;对象:2014 年至 2017 年患有症状性黏膜下肌瘤的女性患者。共有 69 名患者入组,其中 47 名完成。
随机化、线性混合效应模型、假设检验和意向治疗分析。每位患者随机分为口服避孕药/孕激素释放宫内节育器或宫腔镜子宫肌瘤切除术。每位患者均在基线、一个月、三个月和治疗后大于或等于六个月时完成子宫肌瘤症状和健康相关生活质量(UFS-QOL)问卷。
主要结果是健康相关生活质量(HR-QOL),反映在 UFS-QOL 评分上。从线性混合效应模型中构建对比,以比较两种治疗组 UFS-QOL 评分的基线变化。
两组患者的 UFS-QOL 评分在基线时相似。两组患者的 UFS-QOL 评分均有总体改善。手术组的 UFS-QOL 评分改善幅度明显高于药物组。在治疗后≥6 个月时,与药物治疗组相比,手术组的 HR-QOL 担忧、活动、自我意识和症状严重程度评分的改善幅度最大,平均变化评分(95%CI)分别为 35.3、28.9、28.6 和 32.2。
虽然在接受药物或手术治疗的有症状黏膜下肌瘤患者中,整体生活质量改善程度的变化没有统计学差异,但手术治疗后健康相关生活质量评分的改善差异更大。